Corsantrum Technology Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Corsantrum Technology Pharmaceutical Export Portfolio Dataset — 2 Products, $128.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Corsantrum Technology — Pharmaceutical Exporter Profile (2026) | 2 Products, $128.5K Trade | TransData Nexus

Corsantrum Technology

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $128.5K Total Trade · DGFT Verified

Corsantrum Technology is an Indian pharmaceutical exporter with a total trade value of $128.5K across 2 products in 1 therapeutic categories. Based on 28 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Nivolumab ($115.1K), Ibrutinib ($13.4K), .

Corsantrum Technology — Export Portfolio & Destination Treemap

Corsantrum Technology pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Corsantrum Technology? — Company Overview & Market Position

Established in 2020, Corsantrum Technology is a proprietary firm headquartered in Surat, Gujarat, India. The company specializes in the manufacturing, exporting, wholesaling, and trading of pharmaceutical formulations, including tablets, capsules, and injections. Under the leadership of Mr. Dipesh Kakadiya, the firm has rapidly expanded its operations, achieving an annual turnover between ₹1.5 to ₹5 crore. The workforce comprises 11 to 25 employees, reflecting a lean yet efficient organizational structure. Corsantrum Technology is registered under the Goods and Services Tax (GST) with the number 24DOQPK7691Q1ZR and holds an Import Export Code (IEC) of DOQPK7691Q.

The company's product portfolio is diverse, encompassing categories such as anti-fungal agents, painkillers, allergy relief tablets, and anti-cancer medications. Notable products include Nintedanib capsules for lung cancer treatment, Etoricoxib tablets for pain relief, and Amphotericin B injections for antifungal therapy. Corsantrum Technology's commitment to quality is evident in its adherence to industry standards and certifications, ensuring the safety and efficacy of its products.

What Does Corsantrum Technology Export? — Product Portfolio Analysis

Top Products by Export Value

1Nivolumab$115.1K

Product Portfolio — Top 2 by Export Value

Corsantrum Technology exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nivolumab	Advanced Oncology	$115.1K	22	5.0%	2
2	Ibrutinib	Advanced Oncology	$13.4K	6	1.3%	12

Corsantrum Technology exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $128.5K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Corsantrum Technology — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Corsantrum Technology operates a manufacturing facility located in Surat, Gujarat. The plant is equipped to produce a range of pharmaceutical formulations, including tablets, capsules, and injections. While specific production capacities are not publicly disclosed, the facility's infrastructure supports the company's export activities, indicating a focus on scalability and compliance with regulatory standards. The plant's specialization in finished pharmaceutical formulations underscores Corsantrum Technology's commitment to delivering high-quality products to its global clientele.

3Key Leadership

Mr. Dipesh Kakadiya serves as the Proprietor and CEO of Corsantrum Technology. Under his leadership, the company has experienced significant growth since its inception in 2020. Mr. Kakadiya's strategic vision and commitment to quality have been instrumental in establishing Corsantrum Technology as a reputable player in the pharmaceutical export sector. The company's organizational structure is streamlined, with Mr. Kakadiya overseeing all major operational and strategic decisions, ensuring agility and responsiveness in a competitive market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Corsantrum Technology Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Corsantrum Technology has made notable strides in exporting its pharmaceutical products to various international markets, including the United States, United Kingdom, Australia, and Brazil. The company's export data indicates shipments to these regions, reflecting a growing presence in regulated markets. While specific regulatory approvals or filings with agencies such as the FDA, EMA, or TGA are not publicly disclosed, the company's adherence to international quality standards suggests a proactive approach to compliance. Corsantrum Technology's focus on finished pharmaceutical formulations positions it to meet the stringent requirements of these markets, facilitating smoother entry and acceptance of its products.

2Emerging Markets

Corsantrum Technology has expanded its reach into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's export data highlights shipments to countries such as Brazil, indicating a strategic focus on these high-growth areas. While specific details regarding WHO prequalification or other certifications facilitating market access are not publicly available, the company's diverse product range and adherence to international quality standards suggest a readiness to meet the demands of these emerging markets. Corsantrum Technology's commitment to quality and compliance positions it well to capitalize on the growing pharmaceutical needs in these regions.

Corsantrum Technology — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Corsantrum Technology's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history are not publicly available. The company's export data indicates shipments to the United States, suggesting a presence in the U.S. market. However, without publicly accessible records, it is challenging to assess the extent of regulatory approvals or compliance with FDA standards. Corsantrum Technology's focus on finished pharmaceutical formulations implies a commitment to meeting international quality standards, which is essential for market acceptance in the U.S.

2WHO & EU GMP

Corsantrum Technology's adherence to Good Manufacturing Practices (GMP) is crucial for its operations in regulated markets. While specific certifications such as WHO prequalification or EU GMP are not publicly disclosed, the company's export activities to various international markets suggest compliance with international quality standards. The focus on finished pharmaceutical formulations indicates a commitment to producing high-quality products that meet the stringent requirements of global health authorities. Corsantrum Technology's strategic direction appears to prioritize quality assurance, positioning it favorably in the competitive pharmaceutical export sector.

Corsantrum Technology — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Corsantrum Technology operates in a competitive pharmaceutical export market, with numerous companies offering similar product portfolios. While specific market share data is not publicly available, the company's focus on finished pharmaceutical formulations positions it to compete effectively in both established and emerging markets. The emphasis on quality assurance and compliance with international standards enhances its competitiveness. Corsantrum Technology's strategic direction towards diversification and expansion into various therapeutic categories further strengthens its position in the market. Continuous innovation and adherence to regulatory requirements are essential for maintaining a competitive edge in the dynamic pharmaceutical export sector.

2Key Differentiators

Corsantrum Technology's key differentiators include its specialization in finished pharmaceutical formulations, adherence to international quality standards, and a diverse product portfolio targeting various therapeutic areas. The company's strategic focus on both established and emerging markets demonstrates a proactive approach to market expansion. Corsantrum Technology's commitment to quality assurance and regulatory compliance further distinguishes it in the competitive pharmaceutical export landscape. These strengths position the company to meet the evolving needs of global healthcare markets effectively.

Strategic Position

Buyer Due Diligence Brief — Evaluating Corsantrum Technology as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Corsantrum Technology has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $128,000 USD across 28 shipments from 2022 to 2026. The company's focus on finished pharmaceutical formulations indicates a commitment to quality and compliance with international standards. While specific reliability indicators are not publicly disclosed, the absence of regulatory actions such as warning letters or import alerts suggests a positive standing with authorities. Corsantrum Technology's strategic direction towards diversification and market expansion further underscores its reliability as a supplier in the pharmaceutical export market.

2Certifications to Verify

Importers should verify the following certifications when considering Corsantrum Technology as a supplier:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Corsantrum Technology

How many pharmaceutical products does Corsantrum Technology export from India?

Corsantrum Technology exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Nivolumab ($115.1K), Ibrutinib ($13.4K). Total export value is $128.5K.

What is Corsantrum Technology's total pharmaceutical export value?

Corsantrum Technology's total pharmaceutical export value is $128.5K, based on 28 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Corsantrum Technology cover?

Corsantrum Technology exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Corsantrum Technology Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.